Story perspectives

Novo Nordisk's Heart Drug Fails ZEUS Trial, Shares Slide 9%

8/1/2026

Summary

Story summary

Novo Nordisk said on July 31, 2026 that its heart drug ziltivekimab failed the primary endpoint in the ZEUS trial.
The trial of 6,300 patients reported a hazard ratio of 0.99 (95 % CI 0.88-1.11) with no cardiovascular benefit, the drug lowering IL-6 and hs-CRP but raising serious infections.
Shares fell 9.3% to $46.70, wiping out about $30.7 billion, prompting Novo Nordisk to record a Q3 2026 impairment charge and continue the HERMES and ARTEMIS studies.

History

Historical Context

Pfizer’s CETP inhibitor torcetrapib was stopped in December 2006 after the ILLUMINATE Phase III trial showed a 24 % mortality rise among 1,600 patients, echoing earlier failures of dalcetrapib (2012) and evacetrapib (2015). A decade later, Novo Nordisk’s 2026 ZEUS trial of ziltivekimab enrolled 6,300 participants and found a hazard ratio of 0.99, reinforcing regulators’ heightened scrutiny of cardiovascular-risk drugs.

1 of 2

Story summary

Novo Nordisk said on July 31, 2026 that its heart drug ziltivekimab failed the primary endpoint in the ZEUS trial.
The trial of 6,300 patients reported a hazard ratio of 0.99 (95 % CI 0.88-1.11) with no cardiovascular benefit, the drug lowering IL-6 and hs-CRP but raising serious infections.
Shares fell 9.3% to $46.70, wiping out about $30.7 billion, prompting Novo Nordisk to record a Q3 2026 impairment charge and continue the HERMES and ARTEMIS studies.

1 / 2